Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms
Small Science · 2025-11 · 5 (11)
DOI: 10.1002/smsc.202500270 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Small Science, online erschienen am 04.09.2025. Verfasst von Wonkyung Ahn und 4 weiteren Autor:innen. Beteiligte Einrichtung: School of Chemical Engineering and Applied Chemistry Kyungpook National University Daegu 41566 Republic of Korea. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 336 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea.
Abstract (Originalsprache)
Amid the evolving landscape of immunotherapy, the pursuit of safer, more precise, and broadly applicable vaccine platforms has intensified. While conventional technologies—such as lipid nanoparticle‐based mRNA systems—achieved unprecedented success in infectious disease prophylaxis, their limitations in safety and durability have prompted the search for alternatives to address more complex immunological challenges, particularly in oncology. Within this context, extracellular vesicle (EV)‐based vaccines have emerged as a next‐generation platform. These endogenously derived nanoscale vesicles, secreted by nearly all cell types, mirror the immunological identity of their origin and support diverse immune functions. Advances in EV research have enabled modular vaccine design through strategies such as antigen loading, surface engineering, and cytokine‐driven modulation. Depending on their cellular source—dendritic cells, macrophages, lymphocytes, or tumor cells—EVs exhibit distinct immunological properties that allow tailored engagement of immune responses. Rather than acting solely as delivery vehicles, they integrate antigen transport, immune activation, and adjuvant effects within a single structure. Recent progress in EV‐based cancer vaccine development is reviewed, encompassing vesicle biogenesis, engineering strategies, and delivery optimization, alongside emerging preclinical and clinical evidence supporting their translational potential. Finally, key challenges, including vesicle heterogeneity and manufacturing standardization, are outlined as factors that must be addressed to enable clinical advancement.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- School of Chemical Engineering and Applied Chemistry Kyungpook National University Daegu 41566 Republic of Korea.
- Department of Biochemistry & Molecular Biology Korea University College of Medicine Seoul 02842 Republic of Korea.
- Department of Chemical Engineering and Applied Chemistry Chungnam National University Daejeon 34134 Republic of Korea.
ORCID-Profile: Eun Jung Lee
Förderung
- National Research Foundation of Korea
Zitieren
APA
Ahn, W., Lee, Y., Nam, G. H., You, J. B., & Lee, E. J. (2025). Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms. Small Science, 5(11). https://doi.org/10.1002/smsc.202500270
Vancouver
Ahn W, Lee Y, Nam GH, You JB, Lee EJ. Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms. Small Science. 2025;5(11). doi:10.1002/smsc.202500270
BibTeX
@article{Ahn2025,
author = {Ahn, Wonkyung and Lee, Yeram and Nam, Gi-Hoon and You, Jae Bem and Lee, Eun Jung},
title = {Bioengineered Extracellular Vesicles in Emerging Cancer Vaccine Platforms},
journal = {Small Science},
year = {2025},
volume = {5},
number = {11},
doi = {10.1002/smsc.202500270}
}
EUVIMED